Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cartesian Therapeutics Inc (RNAC)

Cartesian Therapeutics Inc (RNAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 604,623
  • Shares Outstanding, K 25,415
  • Annual Sales, $ 26,000 K
  • Annual Income, $ -219,710 K
  • EBIT $ -54 M
  • EBITDA $ -53 M
  • 60-Month Beta 0.59
  • Price/Sales 22.29
  • Price/Cash Flow N/A
  • Price/Book 648.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.78
  • Number of Estimates 4
  • High Estimate -0.61
  • Low Estimate -1.05
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +67.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.50 +29.81%
on 11/14/24
26.50 -24.08%
on 12/06/24
+3.19 (+18.84%)
since 11/12/24
3-Month
14.00 +43.71%
on 09/24/24
26.50 -24.08%
on 12/06/24
+4.05 (+25.20%)
since 09/12/24
52-Week
11.66 +72.48%
on 04/08/24
41.87 -51.95%
on 06/06/24
-1.07 (-5.06%)
since 12/12/23

Most Recent Stories

More News
Insider Sale: Chief Technology Officer of $RNAC (RNAC) Sells 2,901 Shares

Metin Kurtoglu, the Chief Technology Officer of $RNAC ($RNAC), sold 2,901 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.4%...

RNAC : 20.12 (-15.43%)
Cartesian Therapeutics Announces Phase 3 AURORA Trial for Descartes-08 in Myasthenia Gravis Set to Begin in 1H2025

Cartesian Therapeutics details Phase 3 AURORA trial for Descartes-08, targeting myasthenia gravis with promising Phase 2b results.Quiver AI SummaryCartesian Therapeutics, Inc. announced that it is on track...

RNAC : 20.12 (-15.43%)
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

RNAC : 20.12 (-15.43%)
Insider Sale: Chief Technology Officer of $RNAC (RNAC) Sells 32,789 Shares

Metin Kurtoglu, the Chief Technology Officer of $RNAC ($RNAC), sold 32,789 shares of the company on 11-21-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

RNAC : 20.12 (-15.43%)
Cartesian Therapeutics to Present Updated Data on Descartes-08 for Myasthenia Gravis at Cell Therapy Summit

Cartesian Therapeutics will present updated Phase 2b trial data for Descartes-08 at an upcoming cell therapy summit.Quiver AI SummaryCartesian Therapeutics, Inc. announced that it will present updated...

RNAC : 20.12 (-15.43%)
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

RNAC : 20.12 (-15.43%)
Cartesian Therapeutics Announces New Employment Inducement Grants

RNAC : 20.12 (-15.43%)
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

RNAC : 20.12 (-15.43%)
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting

RNAC : 20.12 (-15.43%)
Insider Stock Research: New Fortress Energy, Marvell, and More

October has seen a flurry of insider trading activity across multiple sectors, with key executives making significant stock purchases. New Fortress Energy’s (

PLAY : 25.49 (-13.33%)
DKL : 39.18 (+0.82%)
RNAC : 20.12 (-15.43%)
COHR : 104.08 (+0.23%)
NEOG : 12.49 (-1.65%)
WOR : 39.28 (-3.87%)
NFE : 13.13 (-0.91%)
STTK : 1.2000 (-9.77%)
MRVL : 109.00 (-2.11%)
CAPR : 14.34 (+0.70%)

Business Summary

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with...

See More

Key Turning Points

3rd Resistance Point 29.67
2nd Resistance Point 26.80
1st Resistance Point 23.46
Last Price 20.12
1st Support Level 17.25
2nd Support Level 14.38
3rd Support Level 11.04

See More

52-Week High 41.87
Fibonacci 61.8% 30.33
Fibonacci 50% 26.77
Fibonacci 38.2% 23.20
Last Price 20.12
52-Week Low 11.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar